Thomas Hopkins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Thomas Hopkins has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Raoul Kopelman
Department of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA
4 shared publications - Alan McLean
JILA
3 shared publications Natalie Potter
3 shared publicationsAlexander Cooke
2 shared publicationsJalal Haidar
2 shared publicationsJoseph Isaac
2 shared publications
Latest Publications
- 9 October 2023
- Published by American Chemical Society (ACS) in ACS Materials Letters
- Vol. 5 (11) , 2971-2977
Flexible Synthesis Scheme and Application of AuNP Surface-Conjugatable Metaiodobenzylguanidine Derivatives for Enhanced Cellular Internalization
- 9 October 2023
- Published by American Chemical Society (ACS) in ACS Materials Letters
- Vol. 5 (11) , 2971-2977
Flexible Synthesis Scheme and Application of AuNP Surface-Conjugatable Metaiodobenzylguanidine Derivatives for Enhanced Cellular Internalization
- 27 September 2021
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 4 (10) , 11321-11322
Correction to “Synthesis and Optical Properties of Two-Photon-Absorbing Au25(Captopril)18-Embedded Polyacrylamide Nanoparticles for Cancer Therapy”
- 27 September 2021
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 4 (10) , 11321-11322
Correction to “Synthesis and Optical Properties of Two-Photon-Absorbing Au25(Captopril)18-Embedded Polyacrylamide Nanoparticles for Cancer Therapy”
- 8 January 2020
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 3 (2) , 1420-1430
Synthesis and Optical Properties of Two-Photon-Absorbing Au25(Captopril)18-Embedded Polyacrylamide Nanoparticles for Cancer Therapy
- 8 January 2020
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 3 (2) , 1420-1430
Synthesis and Optical Properties of Two-Photon-Absorbing Au25(Captopril)18-Embedded Polyacrylamide Nanoparticles for Cancer Therapy
- 20 September 2018
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 1 (4) , 1094-1101
Ultracompact Nanotheranostic PEG Platform for Cancer Applications
We present a new targetable nanoconstruct (NC) capable of simultaneously serving as a therapeutic platform for photodynamic therapy (PDT) as well as a magnetic resonance (MR) molecular imaging agent, free of heavy metal atoms. PDT has seen much interest with the introduction of NC-assisted cell-specific targeting of the photosensitizer (PS). The previously reported ultrasmall 8-arm polyethylene glycol amine (8PEGA) NC, with an attached chlorin e6 (Ce6) PS, yielded promising results for PDT of heart arrhythmia, in vivo and ex vivo, on live rat and sheep hearts, respectively, when using targeting peptides for cell-specific ablation of cardio-myocytes. Here we explore the extension of this NC-based PDT to cancer. For this purpose, we switched the targeting peptide from CTP-cys to F3-cys. Notably, the 8PEGA-Ce6 NCs have a superior reactive oxygen species (ROS) production compared to traditional Ce6 encapsulated polyacrylamide (PAAm) NCs, which should be advantageous for PDT. This NC is also cyto-compatible and offers chemical flexibility for the attachment of a choice of targeting peptides. Finally, this label-free 8PEGA NC can be directly and selectively imaged by MRI, using standard spin–echo imaging sequences with large diffusion magnetic field gradients to suppress the water signal. Notably, due to its ultrasmall size this NC is also expected to have improved in vivo penetration and bioelimination, as was already shown in previous biodistribution studies.
- 20 September 2018
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 1 (4) , 1094-1101
Ultracompact Nanotheranostic PEG Platform for Cancer Applications
We present a new targetable nanoconstruct (NC) capable of simultaneously serving as a therapeutic platform for photodynamic therapy (PDT) as well as a magnetic resonance (MR) molecular imaging agent, free of heavy metal atoms. PDT has seen much interest with the introduction of NC-assisted cell-specific targeting of the photosensitizer (PS). The previously reported ultrasmall 8-arm polyethylene glycol amine (8PEGA) NC, with an attached chlorin e6 (Ce6) PS, yielded promising results for PDT of heart arrhythmia, in vivo and ex vivo, on live rat and sheep hearts, respectively, when using targeting peptides for cell-specific ablation of cardio-myocytes. Here we explore the extension of this NC-based PDT to cancer. For this purpose, we switched the targeting peptide from CTP-cys to F3-cys. Notably, the 8PEGA-Ce6 NCs have a superior reactive oxygen species (ROS) production compared to traditional Ce6 encapsulated polyacrylamide (PAAm) NCs, which should be advantageous for PDT. This NC is also cyto-compatible and offers chemical flexibility for the attachment of a choice of targeting peptides. Finally, this label-free 8PEGA NC can be directly and selectively imaged by MRI, using standard spin–echo imaging sequences with large diffusion magnetic field gradients to suppress the water signal. Notably, due to its ultrasmall size this NC is also expected to have improved in vivo penetration and bioelimination, as was already shown in previous biodistribution studies.